Mamta Jain, MD, MPH

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Gilead Sciences
    Topic: 
    HIV, Hepatits C, COVID-19
    Relationship end date: 
    01/02/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Janssen
    Topic: 
    HIV, Influenza
    Relationship end date: 
    12/31/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Merck
    Topic: 
    HIV
    Relationship end date: 
    12/31/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    GlaxoSmithKline
    Topic: 
    HIV
    Relationship end date: 
    12/30/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Regeneron
    Topic: 
    COVID-19
    Relationship end date: 
    12/31/2020
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Vasogene
    Topic: 
    HIV
    Date added: 
    01/31/2022
    Relationship end date: 
    01/30/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Gilead Sciences
    Topic: 
    COVID-19
    Date added: 
    01/31/2022
    Relationship end date: 
    12/31/2020
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    ACTHIV
    Topic: 
    HIV
    Date added: 
    01/31/2022
    Relationship end date: 
    12/30/2022
Return to 122 Infectious Diseases and Geographic Medicine Division Grand Rounds: " “COVID-19 Treatment with Monoclonal/Polyclonal Antibodies and Impact of Variants: What we have learned in Hospitalized Patients”(020322)